B. Braun Receives FDA Approval of Daytona Beach Pharmaceutical Manufacturing Site
- B.Braun Medical, Inc.
BETHLEHEM, Pa., Jan. 28, 2022 /PRNewswire/ — B. Braun Medical Inc. (B. Braun), a leader in infusion therapy and pain management, today announced that the company has received final approval by the U.S. Food & Drug Administration (FDA) for its new pharmaceutical manufacturing plant in Daytona Beach, FL. The site will produce 0.9% Sodium Chloride for Injection available in B. Braun’s Excel® Plus IV Bags in 1,000 mL and 500 mL sizes. Consistent with B. Braun’s decades-long commitment to protect patients from exposure to harmful chemicals, the Excel Plus IV bags are not made with PVC, DEHP or natural rubber latex. Read more…
Related Reading
Event / Regulatory Affairs
FDA For-Cause Inspections Targeting Medical Device Manufacturers: Navigating the Process, Mitigating Risks
April 13, 2026
10:00 AM – 11:00 AM
Join Hogan Lovells in this webinar will examine FDA for-cause inspections as they relate to medical device manufacturers.
Event / Emerging Policy Response Resources / Global & Trade / Government & Legislative Affairs / Supply Chain / Tariffs
Navigating the ACCESS & TEMPO Models: A Direct Dialogue with CMMI & FDA Leaders
On Demand
Watch AdvaMed’s® exclusive member-only webinar featuring a direct dialogue with CMS Innovation Center leadership on the newly released ACCESS & TEMPO Model. Attendees will gain critical insights into model performance metrics, payment pathways, and opportunities for the MedTech industry.
Resource / Artificial Intelligence (AI) / Coverage & Payment / Digital Health / Regulatory Affairs
AdvaMed® Comment Letter to ASTP/ONC: Accelerating AI Adoption in Clinical Care
February 24, 2026
AdvaMed’s® Comment Letter to ASTP/ONC, outlines concrete policy reforms across FDA oversight, CMS payment pathways, and HIPAA data-sharing rules to accelerate patient access to AI-enabled medical technologies. As AI-enabled medical devices transform patient care, outdated regulatory, coverage, and privacy frameworks are slowing the pace of adoption.
News / Artificial Intelligence (AI) / Regulatory Affairs
i-GENTIC AI Launches Context-Aware MedTech Agents to Strengthen FDA 510(k) Submission Consistency
February 23, 2026
PALO ALTO, Calif., Feb. 11, 2026 i-GENTIC AI today announced a new suite of context-aware, multilingual MedTech agents designed to help medical device manufacturers improve the quality and consistency of FDA 510(k) submissions. Preparing a 510(k) often takes months, yet many submissions require additional information requests or are rejected due to inconsistencies across documents, evidence, and claims, creating delays and added costs for manufacturers.
News / Global & Trade / Tariffs
ICYMI: AdvaMed’s Scott Whitaker on Supreme Court Tariffs Decision, Next Steps
February 23, 2026
Scott Whitaker, president and CEO ofAdvaMed®, the world’s largest trade association representing medtech innovators, released the following statement after Fridays’ Supreme Court ruling on tariffs. Today, he published a more fulsome readout on LinkedIn, available here.
Event / Emerging Policy Response Resources / Global & Trade / Government & Legislative Affairs / Supply Chain / Tariffs
The Supreme Court Struck Down IEEPA Tariffs – What Medtech Needs To Know
Now On Demand
The U.S. Supreme Court recently marked a significant shift in the tariff landscape, learn what that means for your organization.
Blog / Regulatory Affairs
Why Practical FDA Submissions Training Makes the Difference
February 17, 2026
Explore AdvaMed’s Medical Device Submissions Workshop Series from practical submission strategies to live expert insights you can apply immediately.
News / Global & Trade / Supply Chain / Tariffs
AdvaMed® Supports United States-Mexico-Canada Agreement Renewal
February 12, 2026
WASHINGTON—AdvaMed, the MedTech Association®, representing more than 650 medtech and health tech companies, the majority small businesses, today expressed support for renewal of the United States-Mexico-Canada Agreement (USMCA). Scott Whitaker,AdvaMed® president and CEO, made the following comment on the renewal.